Business Advisory Board
Former CEO, Labrys and KAI
Steve has over twenty five years of pharmaceutical, biotechnology and start-up experience in the life science industry. Most recently, Steve was President, CEO, and Director of Labrys Biologics, Inc. from December 2012 until it was acquired by Teva Pharmaceuticals in July 2014.
Steve was President, CEO and Director of KAI Pharmaceuticals, Inc. from October 2004 until it was acquired by Amgen in July 2012.
Steve began his career in new product planning at Eli Lilly followed by California Biotechnology (Scios/J&J). Steve then became Vice President of Business Development at Isis Pharmaceuticals. In 1999 Steve joined Sunesis Pharmaceuticals as Senior Vice President and member of the board of directors, and later, Chief Business Officer. Steve was also Senior Vice President of Commercial Operations at Exelixis.
Steve is a director of Ocera Therapeutics, Chrono Therapeutics, and Cascadian Therapeutics, and a Trustee of Middlebridge School. Steve is also on the advisory board of Antiva Biosciences, Allakos Inc., and interim CEO of PIONYR Immunotherapeutics.
Steve has a bachelor degree in biology from Brown University and a Masters in Management from the Kellogg School of Northwestern University.